Protalix Biotherapeutics Inc (PLX)

678.00
+14.00(+2.09%)
  • Volume:
    141,547
  • Bid/Ask:
    679.00/679.00
  • Day's Range:
    660.00 - 678.00

PLX Overview

Prev. Close
664
Day's Range
660-678
Revenue
-
Open
660
52 wk Range
654-2,290
EPS
-1.26
Volume
141,547
Market Cap
299.92M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
275,692
P/E Ratio
-
Beta
1.74
1-Year Change
-45.98%
Shares Outstanding
45,382,831
Next Earnings Date
Aug 12, 2021
What is your sentiment on Protalix Biotherapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Protalix Biotherapeutics Inc News

Protalix Biotherapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuySellStrong SellStrong Sell
SummaryStrong BuyBuySellStrong SellStrong Sell

Protalix Biotherapeutics Inc Company Profile

Protalix Biotherapeutics Inc Company Profile

Employees
207
Market
Israel

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Read More
  • When its gonna make money?
    0
    • sta per mollare...
      0
      • bottom zone ...we at buying levels
        1
        • sotto 2 $...oggi....scappare...
          0
          • come lo sai_??
            0
          • come lo sai_??
            0
        • it' will be up?
          2
          • Not so much in near term
            0
        • No reason they didn't get FDA approve yet.. only matter of time - huge upside
          0
          • Let's hope they go up a little this week 😅
            0
        • this stock aint coming back anytime soon. sell
          1
          • bottom??
            0
            • Thought something better, to be honest..
              1
              • Moving... ok, I'm averaging a little.
                0
                • Let's rally a little bit, why not?
                  0
                  • Quick buy call with 6$ inteaday target
                    0
                    • Wuick buy call on PLX.. cmp 3.65 and 38% down tofay will close in green
                      0
                      • buy now
                        2
                        • Just bought @ 3.3 Allah knows well.
                          0
                          • 3.2
                            0
                            • sky rocket to the moon the voyage starts this month.
                              0
                              • what r they selling ....poe?
                                0
                                • PLX will go up before the new year.  Not sure it will sky rocket though.
                                  1
                                  • Any chance it will go up?
                                    0
                                    • any chance this stock will sky rocket ?
                                      0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.